EP-104GI consists of coated FP crystals that release locally via diffusion at a pre-defined rate to reduce peak concentrations and prolong therapeutic window. RESOLVE (NCT05608681) is a Phase 1b, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics...
#泰剧逐月之月2[超话]# Ep.10预告 四哥&四嫂篇 这段完整版来了!四嫂对我们四哥好点呐[害羞] http://t.cn/Ai8s63pP
S689 Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis.doi:10.14309/01.ajg.0001032124.58501.0cMalone, Amanda PhD...
S644Pharmacokinetics and Local Tolerability of EP-104GI, an Extended-Release Formulation of Fluticasone Propionate for Treatment of Eosinophilic Esophagitis, After Intra-Esophageal Injection in Mini-Pigsdoi:10.14309/01.ajg.0001031944.76439.b6Webb, Murray PhD...